(Q26824869)

language of work or name

1 reference

February 2013

1 reference

American Journal of Transplantation

published in

1 reference

volume

13 Suppl 3

1 reference

page(s)

24-40; quiz 40

1 reference

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

cites work

1 reference

GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.

21 January 2018

1 reference

The 'indirect' effects of cytomegalovirus infection

21 January 2018

1 reference

Infection in solid-organ transplant recipients

21 January 2018

1 reference

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy

21 January 2018

1 reference

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

21 January 2018

1 reference

Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients

21 January 2018

1 reference

Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States

21 January 2018

1 reference

Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection

21 January 2018

1 reference

Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

21 January 2018

1 reference

Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation

21 January 2018

1 reference

Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

21 January 2018

1 reference

Immunosuppressive therapy and infection after kidney transplantation.

21 January 2018

1 reference

Epidemiology and risk factors for late infection in solid organ transplant recipients.

21 January 2018

1 reference

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

21 January 2018

1 reference

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients

21 January 2018

1 reference

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

21 January 2018

1 reference

Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients

21 January 2018

1 reference

Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.

21 January 2018

1 reference

Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.

21 January 2018

1 reference

Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection

21 January 2018

1 reference

Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation.

21 January 2018

1 reference

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

21 January 2018

1 reference

Cellular immune responses to cytomegalovirus in renal transplant recipients

21 January 2018

1 reference

PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy

21 January 2018

1 reference

Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.

21 January 2018

1 reference

Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients

21 January 2018

1 reference

Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood.

21 January 2018

1 reference

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

Monitoring human cytomegalovirus infection in transplant recipients

21 January 2018

1 reference

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

21 January 2018

1 reference

Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.

21 January 2018

1 reference

Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays

21 January 2018

1 reference

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

21 January 2018

1 reference

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

21 January 2018

1 reference

Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease

21 January 2018

1 reference

The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease

21 January 2018

1 reference

Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents.

21 January 2018

1 reference

Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma?

21 January 2018

1 reference

Interlaboratory comparison of cytomegalovirus viral load assays.

21 January 2018

1 reference

Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective

21 January 2018

1 reference

Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients

21 January 2018

1 reference

The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response

21 January 2018

1 reference

Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.

21 January 2018

1 reference

Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry

21 January 2018

1 reference

Definitions of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients

21 January 2018

1 reference

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

21 January 2018

1 reference

Cytomegalovirus drug resistance and clinical implications

21 January 2018

1 reference

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

Relapsing cytomegalovirus infection in solid organ transplant recipients

21 January 2018

1 reference

Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients

21 January 2018

1 reference

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy

21 January 2018

1 reference

Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients

21 January 2018

1 reference

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

21 January 2018

1 reference

Ganciclovir-resistant cytomegalovirus in organ transplant recipients

21 January 2018

1 reference

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

21 January 2018

1 reference

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study

21 January 2018

1 reference

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes

21 January 2018

1 reference

Antiviral drug resistance of human cytomegalovirus

21 January 2018

1 reference

Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms

21 January 2018

1 reference

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

21 January 2018

1 reference

Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus

21 January 2018

1 reference

Human cytomegalovirus resistance to antiviral drugs

21 January 2018

1 reference

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis

21 January 2018

1 reference

Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens

21 January 2018

1 reference

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

21 January 2018

1 reference

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients

21 January 2018

1 reference

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

21 January 2018

1 reference

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

21 January 2018

1 reference

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

21 January 2018

1 reference

Update in management of ganciclovir-resistant cytomegalovirus infection

21 January 2018

1 reference

Utility of leflunomide in the treatment of complex cytomegalovirus syndromes

21 January 2018

1 reference

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.

21 January 2018

1 reference

Influence of cytomegalovirus disease in outcome of solid organ transplant patients.

21 January 2018

1 reference

The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.

21 January 2018

1 reference

Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation

21 January 2018

1 reference

Hypomagnesemia and the risk of new-onset diabetes after liver transplantation

21 January 2018

1 reference

Cytomegalovirus infection: a driving force in human T cell immunosenescence

21 January 2018

1 reference

Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.

21 January 2018

1 reference

Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.

21 January 2018

1 reference

CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up

21 January 2018

1 reference

Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival.

21 January 2018

1 reference

Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis

21 January 2018

1 reference

Late hepatic artery thrombosis after orthotopic liver transplantation

21 January 2018

1 reference

Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.

21 January 2018

1 reference

Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function

21 January 2018

1 reference

Management of cytomegalovirus infection in solid organ transplantation

21 January 2018

1 reference

Quantification of Cytomegalovirus DNA in BAL Fluid

21 January 2018

1 reference

Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients

21 January 2018

1 reference

Cytomegalovirus Replication Within the Lung Allograft Is Associated With Bronchiolitis Obliterans Syndrome

21 January 2018

1 reference

Hepatic artery thrombosis following orthotopic liver transplantation: A 10-year experience from a single centre in the United Kingdom

21 January 2018

1 reference

7 January 2021

Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study

1 reference

7 January 2021

Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients

1 reference

7 January 2021

Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease

1 reference

7 January 2021

Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection

1 reference

7 January 2021

Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens

1 reference

7 January 2021

Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients

1 reference

7 January 2021

Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation

1 reference

7 January 2021

Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group

1 reference

7 January 2021

Evaluation of Cytomegalovirus (CMV)–Specific T Cell Immune Reconstitution Revealed That Baseline Antiviral Immunity, Prophylaxis, or Preemptive Therapy but not Antithymocyte Globulin Treatment Contribute to CMV‐Specific T Cell Reconstitution in K

1 reference

7 January 2021

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

7 January 2021

The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients

1 reference

7 January 2021

Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients

1 reference

7 January 2021

Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients

1 reference

7 January 2021

Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation

1 reference

7 January 2021

Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk

1 reference

7 January 2021

The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients

1 reference

7 January 2021

Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations

1 reference

7 January 2021

Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide

1 reference

7 January 2021

Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure

1 reference

7 January 2021

Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients

1 reference

7 January 2021

Differences in CMV-Specific T-Cell Levels and Long-Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation

1 reference

7 January 2021

Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation

1 reference

7 January 2021

Cytomegalovirus in solid organ transplant recipients

1 reference

7 January 2021

Putting the IMPACT study into perspective: should CMV prophylaxis be extended to 6 months for high risk transplants?

1 reference

7 January 2021

First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246

1 reference

7 January 2021

Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials

1 reference

7 January 2021

High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy

1 reference

7 January 2021

Identifiers

DOI

10.1111/AJT.12006

1 reference

Consolidated OpenCitations Corpus – April 2017

4684686

4684686

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference